Prolonged versus short-term intravenous infusion of antipseudomonal β-lactams for patients with sepsis: a systematic review and meta-analysis of randomised trials

2016, Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015, Lancet, 388, 1459, 10.1016/S0140-6736(16)31012-1 Karlsson, 2009, Long-term outcome and quality-adjusted life years after severe sepsis, Crit Care Med, 37, 1268, 10.1097/CCM.0b013e31819c13ac Perner, 2017, Sepsis: frontiers in supportive care, organisation and research, Intensive Care Med, 43, 496, 10.1007/s00134-017-4677-4 Falagas, 2016, The antibiotic pipeline for multi-drug resistant gram negative bacteria: what can we expect?, Expert Rev Anti Infect Ther, 14, 747, 10.1080/14787210.2016.1204911 Falagas, 2016, Fosfomycin, Clin Microbiol Rev, 29, 321, 10.1128/CMR.00068-15 Lin, 2015, Mechanisms of antibiotic resistance, Front Microbiol, 6, 34, 10.3389/fmicb.2015.00034 Roberts, 2009, A systematic review on clinical benefits of continuous administration of beta-lactam antibiotics, Crit Care Med, 37, 2071, 10.1097/CCM.0b013e3181a0054d Moriyama, 2009, Continuous-infusion beta-lactam antibiotics during continuous venovenous hemofiltration for the treatment of resistant gram-negative bacteria, Ann Pharmacother, 43, 1324, 10.1345/aph.1L638 Abdul-Aziz, 2015, Applying pharmacokinetic/pharmacodynamic principles in critically ill patients: optimizing efficacy and reducing resistance development, Semin Respir Crit Care Med, 36, 136, 10.1055/s-0034-1398490 Falagas, 2013, Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/tazobactam: a systematic review and meta-analysis, Clin Infect Dis, 56, 272, 10.1093/cid/cis857 Kasiakou, 2005, Continuous versus intermittent intravenous administration of antibiotics: a meta-analysis of randomised controlled trials, Lancet Infect Dis, 5, 581, 10.1016/S1473-3099(05)70218-8 Korbila, 2013, Extended or continuous versus short-term intravenous infusion of cephalosporins: a meta-analysis, Expert Rev Anti Infect Ther, 11, 585, 10.1586/eri.13.44 Shiu, 2013, Continuous versus intermittent infusions of antibiotics for the treatment of severe acute infections, Cochrane Database Syst Rev, 10.1002/14651858.CD008481.pub2 Dulhunty, 2015, A multicenter randomized trial of continuous versus intermittent beta-lactam infusion in severe sepsis, Am J Respir Crit Care Med, 192, 1298, 10.1164/rccm.201505-0857OC Abdul-Aziz, 2016, Beta-lactam infusion in severe sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis, Intensive Care Med, 42, 1535, 10.1007/s00134-015-4188-0 Chytra, 2012, Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open-label controlled trial, Crit Care, 16, R113, 10.1186/cc11405 Dulhunty, 2013, Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial, Clin Infect Dis, 56, 236, 10.1093/cid/cis856 Guyatt, 2008, What is quality of evidence and why is it important to clinicians?, BMJ, 336, 995, 10.1136/bmj.39490.551019.BE Mantel, 1959, Statistical aspects of the analysis of data from retrospective studies of disease, J Natl Cancer Inst, 22, 719 Egger, 1997, Bias in meta-analysis detected by a simple, graphical test, BMJ, 315, 629, 10.1136/bmj.315.7109.629 Okimoto, 2009, Clinical effects of continuous infusion and intermittent infusion of meropenem on bacterial pneumonia in the elderly, Nihon Kokyuki Gakkai Zasshi, 47, 553 Angus, 2000, Pharmacokinetic-pharmacodynamic evaluation of ceftazidime continuous infusion vs intermittent bolus injection in septicaemic melioidosis, Br J Clin Pharmacol, 50, 184, 10.1111/j.1365-2125.2000.00179.x Bao, 2016, Clinical outcomes of extended versus intermittent administration of piperacillin/tazobactam for the treatment of hospital-acquired pneumonia: a randomized controlled trial, Eur J Clin Microbiol Infect Dis, 36, 459, 10.1007/s10096-016-2819-1 Buck, 2005, Pharmacokinetics of piperacillin-tazobactam: intermittent dosing versus continuous infusion, Int J Antimicrob Agents, 25, 62, 10.1016/j.ijantimicag.2004.08.012 Cotrina-Luque, 2016, Continuous versus intermittent piperacillin/tazobactam infusion in infection due to or suspected pseudomonas aeruginosa, Int J Clin Pharm, 38, 70, 10.1007/s11096-015-0208-y Cousson, 2005, [Pharmacodynamic interest of ceftazidime continuous infusion vs intermittent bolus administration in patients with severe nosocomial pneumonia], Pathol Biol, 53, 546, 10.1016/j.patbio.2005.06.002 Georges, 2005, Cefepime in critically ill patients: continuous infusion vs. an intermittent dosing regimen, Int J Clin Pharmacol Ther, 43, 360, 10.5414/CPP43360 Hanes, 2000, Intermittent and continuous ceftazidime infusion for critically ill trauma patients, Am J Surg, 179, 436, 10.1016/S0002-9610(00)00388-3 Lagast, 1983, Treatment of gram-negative bacillary septicemia with cefoperazone, Eur J Clin Microbiol, 2, 554, 10.1007/BF02016564 Lau, 2006, Randomized, open-label, comparative study of piperacillin-tazobactam administered by continuous infusion versus intermittent infusion for treatment of hospitalized patients with complicated intra-abdominal infection, Antimicrob Agents Chemother, 50, 3556, 10.1128/AAC.00329-06 Lips, 2014, Pharmacokinetics of imipenem in critically ill patients during empirical treatment of nosocomial pneumonia: a comparison of 0·5-h and 3-h infusions, Int J Antimicrob Agents, 44, 358, 10.1016/j.ijantimicag.2014.05.011 Lubasch, 2003, Optimizing ceftazidime pharmacodynamics in patients with acute exacerbation of severe chronic bronchitis, J Antimicrob Chemother, 51, 659, 10.1093/jac/dkg111 McNabb, 2001, Cost-effectiveness of ceftazidime by continuous infusion versus intermittent infusion for nosocomial pneumonia, Pharmacotherapy, 21, 549, 10.1592/phco.21.6.549.34539 Rafati, 2006, Clinical efficacy of continuous infusion of piperacillin compared with intermittent dosing in septic critically ill patients, Int J Antimicrob Agents, 28, 122, 10.1016/j.ijantimicag.2006.02.020 Roberts, 2010, First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis, Int J Antimicrob Agents, 35, 156, 10.1016/j.ijantimicag.2009.10.008 Sakka, 2007, Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipenem-cilastatin in critically ill patients in a randomized, controlled trial, Antimicrob Agents Chemother, 51, 3304, 10.1128/AAC.01318-06 Wang, 2009, Experience with extended-infusion meropenem in the management of ventilator-associated pneumonia due to multidrug-resistant Acinetobacter baumannii, Int J Antimicrob Agents, 33, 290, 10.1016/j.ijantimicag.2008.09.012 Wang, 2014, Comparison of 3-hour and 30-minute infusion regimens for meropenem in patients with hospital acquired pneumonia in intensive care unit: a randomized controlled clinical trial, Zhonghua Wei Zhong Bing Ji Jiu Yi Xue, 26, 644 Roberts, 2016, Continuous versus intermittent beta-lactam infusion in severe sepsis. A meta-analysis of individual patient data from randomized trials, Am J Respir Crit Care Med, 194, 681, 10.1164/rccm.201601-0024OC Siempos, 2007, Carbapenems for the treatment of immunocompetent adult patients with nosocomial pneumonia, Eur Respir J, 29, 548, 10.1183/09031936.00080206 Acosta Garcia, 2012, Piperacillin-tazobactam in continuous or expanded perfusion vs intermittent perfusion, Farm Hosp, 36, 424, 10.1016/j.farma.2011.06.013 Tamma, 2011, Does prolonged beta-lactam infusions improve clinical outcomes compared to intermittent infusions? A meta-analysis and systematic review of randomized, controlled trials, BMC Infect Dis, 11, 181, 10.1186/1471-2334-11-181 Teo, 2014, Prolonged infusion versus intermittent boluses of beta-lactam antibiotics for treatment of acute infections: a meta-analysis, Int J Antimicrob Agents, 43, 403, 10.1016/j.ijantimicag.2014.01.027 Yang, 2015, Clinical outcomes with alternative dosing strategies for piperacillin/tazobactam: a systematic review and meta-analysis, PLoS One, 10, e0116769, 10.1371/journal.pone.0116769 Yusuf, 2014, Prolonged vs intermittent infusion of piperacillin/tazobactam in critically ill patients: a narrative and systematic review, J Crit Care, 29, 1089, 10.1016/j.jcrc.2014.07.033 Lal, 2016, Prolonged versus intermittent infusion of beta-lactams for the treatment of nosocomial pneumonia: a meta-analysis, Infect Chemother, 48, 81, 10.3947/ic.2016.48.2.81 Kalil, 2016, Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society, Clin Infect Dis, 63, e61, 10.1093/cid/ciw353 Limited Boselli, 2008, Alveolar concentrations of piperacillin/tazobactam administered in continuous infusion to patients with ventilator-associated pneumonia, Crit Care Med, 36, 1500, 10.1097/CCM.0b013e318170ba21 Kim, 2001, Pharmacokinetic and pharmacodynamic profile of high dose extended interval piperacillin-tazobactam, J Antimicrob Chemother, 48, 259, 10.1093/jac/48.2.259 Georges, 2012, Ceftazidime dosage regimen in intensive care unit patients: from a population pharmacokinetic approach to clinical practice via Monte Carlo simulations, Br J Clin Pharmacol, 73, 588, 10.1111/j.1365-2125.2011.04117.x Bliziotis, 2005, Effect of aminoglycoside and beta-lactam combination therapy versus beta-lactam monotherapy on the emergence of antimicrobial resistance: a meta-analysis of randomized, controlled trials, Clin Infect Dis, 41, 149, 10.1086/430912 Paul, 2014, Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis, Cochrane Database Syst Rev, 1 Paul, 2003, Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis, BMJ, 326, 1111, 10.1136/bmj.326.7399.1111 Vardakas, 2005, Role of glycopeptides as part of initial empirical treatment of febrile neutropenic patients: a meta-analysis of randomised controlled trials, Lancet Infect Dis, 5, 431, 10.1016/S1473-3099(05)70164-X Vardakas, 2013, beta-Lactam plus aminoglycoside or fluoroquinolone combination versus beta-lactam monotherapy for Pseudomonas aeruginosa infections: a meta-analysis, Int J Antimicrob Agents, 41, 301, 10.1016/j.ijantimicag.2012.12.006 Vardakas, 2017, Fluoroquinolones or macrolides in combination with beta-lactams in adult patients hospitalized with community acquired pneumonia: a systematic review and meta-analysis, Clin Microbiol Infect, 46, 234, 10.1016/j.cmi.2016.12.002 Tumbarello, 2015, Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study, J Antimicrob Chemother, 70, 2133, 10.1093/jac/dkv086 Tumbarello, 2012, Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy, Clin Infect Dis, 55, 943, 10.1093/cid/cis588 Falagas, 2012, Impact of antibiotic MIC on infection outcome in patients with susceptible Gram-negative bacteria: a systematic review and meta-analysis, Antimicrob Agents Chemother, 56, 4214, 10.1128/AAC.00663-12 Mavros, 2012, Impact of vancomycin minimum inhibitory concentration on clinical outcomes of patients with vancomycin-susceptible Staphylococcus aureus infections: a meta-analysis and meta-regression, Int J Antimicrob Agents, 40, 496, 10.1016/j.ijantimicag.2012.07.023 Abdul-Aziz, 2012, Continuous beta-lactam infusion in critically ill patients: the clinical evidence, Ann Intensive Care, 2, 37, 10.1186/2110-5820-2-37 Hoban, 2015, Global in vitro activity of tigecycline and comparator agents: Tigecycline Evaluation and Surveillance Trial 2004–2013, Ann Clin Microbiol Antimicrob, 14, 27, 10.1186/s12941-015-0085-1 Rhomberg, 2009, Summary trends for the meropenem yearly susceptibility test information collection program: a 10-year experience in the United States (1999–2008), Diagn Microbiol Infect Dis, 65, 414, 10.1016/j.diagmicrobio.2009.08.020 Lodise, 2007, Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy, Clin Infect Dis, 44, 357, 10.1086/510590 Awissi, 2015, Pharmacokinetics of an extended 4-hour infusion of piperacillin-tazobactam in critically ill patients undergoing continuous renal replacement therapy, Pharmacotherapy, 35, 600, 10.1002/phar.1604 Isla, 2016, Meropenem dosing requirements against Enterobacteriaceae in critically ill patients: influence of renal function, geographical area and presence of extended-spectrum beta-lactamases, Eur J Clin Microbiol Infect Dis, 35, 511, 10.1007/s10096-015-2568-6 Kitzes-Cohen, 2002, Pharmacokinetics and pharmacodynamics of meropenem in critically ill patients, Int J Antimicrob Agents, 19, 105, 10.1016/S0924-8579(01)00474-5 Seyler, 2011, Recommended beta-lactam regimens are inadequate in septic patients treated with continuous renal replacement therapy, Crit Care, 15, R137, 10.1186/cc10257 Arzuaga, 2005, Influence of renal function on the pharmacokinetics of piperacillin/tazobactam in intensive care unit patients during continuous venovenous hemofiltration, J Clin Pharmacol, 45, 168, 10.1177/0091270004269796 Isla, 2005, Meropenem and continuous renal replacement therapy: in vitro permeability of 2 continuous renal replacement therapy membranes and influence of patient renal function on the pharmacokinetics in critically ill patients, J Clin Pharmacol, 45, 1294, 10.1177/0091270005280583 Isla, 2008, Population pharmacokinetics of meropenem in critically ill patients undergoing continuous renal replacement therapy, Clin Pharmacokinet, 47, 173, 10.2165/00003088-200847030-00003 Jamal, 2014, The impact of variation in renal replacement therapy settings on piperacillin, meropenem, and vancomycin drug clearance in the critically ill: an analysis of published literature and dosing regimens*, Crit Care Med, 42, 1640, 10.1097/CCM.0000000000000317 Petersson, 2016, Standard dosing of piperacillin and meropenem fail to achieve adequate plasma concentrations in ICU patients, Acta Anaesthesiol Scand, 60, 1425, 10.1111/aas.12808 Singer, 2016, The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3), JAMA, 315, 801, 10.1001/jama.2016.0287 Grammatikos, 2008, Optimal duration of the antimicrobial treatment of ventilator-acquired pneumonia, Expert Rev Anti Infect Ther, 6, 861, 10.1586/14787210.6.6.861 Kaziani, 2017, Duration of pneumonia therapy and the role of biomarkers, Curr Opin Infect Dis, 30, 221, 10.1097/QCO.0000000000000351 Rafailidis, 2009, Meta-analyses on the optimization of the duration of antimicrobial treatment for various infections, Infect Dis Clin North Am, 23, 269, 10.1016/j.idc.2009.01.009 Daneman, 2016, Duration of antimicrobial treatment for bacteremia in Canadian critically ill patients, Crit Care Med, 44, 256, 10.1097/CCM.0000000000001393